Page 24 - Pharma Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

-        Number of executions on sell side on semester: 609 -        Traded volume on buy side on semester: 457,955 shares for € 1,916,480.01 -        Traded volume on sell side on semester: 310,810 shares for € 1,312,111.94 •        the following resources appeared on the liquidity account when the activity started: -        0 shares -        € 500,000.00 The liquidity agreement complies with AMF Decision n° 2018-01 dated 2nd July 2018, introducing liquidity agreements on equity securities as permitted market practice. About Nicox Nico...

Nicox: Half-year liquidity contract statement with Kepler Cheuvreux July 6, 2021 - release at 7:30 am CET Sophia Antipolis, France Under the liquidity contract entered into between NICOX and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th 2021: - 218,919 shares - Number of executions on sell side on semester: 1,298 - Traded volume on buy side on semester: 978,682 shares for € 4,245,529.01 - Traded volume on sell side on semester: 906,908 shares for € 3,977,929.37 As a reminder : • the following resources appear...

® Agreement Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that it has amended its March 2019 license agreement with Ocumension Therapeutics, under which Ocumension has exclusive rights to develop and commercialize ZERVIATE ® (cetirizine ophthalmic solution), 0.24% in the Chinese and the majority of South East Asian markets. Under the amended agreement, Ocumension will immediately pay Nicox $2 million in full advance payment of the future development and regulatory milestones for the product. Amendments were mad...

Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2b Blepharitis Trial July 2nd, 2021 - release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, announced that the last patient in the NCX 4251 Mississippi Phase 2b blepharitis clinical trial has now completed the two-week treatment phase as well as the required two-week follow up period. Top-line results are expected to be announced in September 2021. " Mississippi trial Phase 2 at Nicox, amount used to guide the future development of NCX 4251 . We ...

Nicox partners with Laboratorios Grin to bring ZERVIATE to Mexico TM to Mexico Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced the signature of an exclusive license agreement with Laboratorios Grin, a wholly-owned subsidiary of Lupin Limited, for the registration and commercialization of ZERVIATE TM (cetirizine ophthalmic solution), 0.24% for the treatment of ocular itching associated with allergic conjunctivitis in Mexico. Grin is a Mexican specialty pharmaceutical company engaged in the development, manufactur...